Celluris

Celluris is the first company in Latin America to develop personalized treatment for cancer patients through CAR-T immunotherapy. This technique is based on the modification of the patient’s own cells into recognizing the tumor as a target, fighting it accurately. This way, revolutionizing cancer treatment through an innovative immunotherapy approach is the purpose of Celluris. We are the Brazilian reference company in cell therapy treatments to fight cancer. To meet such a relevant challenge, we used Chimeric Antigen Receptor T-cells Therapy (CAR-T), currently available in the United States, European Union countries and Israel. In Brazil, it was regulated by the National Health Agency (Anvisa) in February 2020. This therapeutic alternative has shown impressive results in clinical tests in several countries during the treatment of patients affected by hematological and solid tumors. In Brazil, we are the first company dedicated to this field.